Ganga Pharma Key Ratios
BSE: 539680
₹12.00
₹-1.97
(-14.10%)
As on 23-Jan-2026IST
Market cap
₹7 Cr
Revenue (TTM)
₹3 Cr
P/E Ratio
89.8
P/B Ratio
0.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | 74.22 | -3.60 | 1.95 | -3.05 |
| EBIT | -- | 135.34 | -2,033.92 | -321.46 | -186.70 |
| Net Profit | -- | 57.41 | 69.52 | 27.77 | -15.98 |
| EPS | -- | 57.49 | 69.50 | 20.54 | -18.86 |
| Book Value | -- | -- | 1.23 | 0.34 | 0.42 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| -2.62 | -1.85 | -6.17 | 0.31 | -1.99 |
| Net Margin
| 1.83 | 1.53 | 2.57 | 1.57 | 1.36 |
| Return on equity
| 0.91 | 0.76 | 1.22 | 0.78 | 0.72 |
| Return on Capital
| 3.25 | 3.30 | 3.22 | 3.16 | 3.38 |
| Return on Assets
| 0.65 | 0.54 | 0.90 | 0.56 | 0.49 |
| Debt to Equity (x)
| -- | -- | 0.22 | 0.21 | 0.34 |
Profitability
ROCE
3.22
Lower than Peers by 11.01
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
3.22
|
3.16
|
3.38
|
3.41
|
3.36
|
|
Peer Median
|
14.23
|
13.72
|
22.53
|
4.15
|
--
|
ROE
1.22
Lower than Peers by 8.12
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
1.22
|
0.78
|
0.72
|
0.70
|
0.38
|
|
Peer Median
|
9.34
|
9.55
|
16.92
|
2.80
|
--
|
ROA
0.90
Lower than Peers by 4.56
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
0.90
|
0.56
|
0.49
|
0.48
|
0.27
|
|
Peer Median
|
5.46
|
5.81
|
9.16
|
1.50
|
--
|
EBIT Margin
-6.17
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
-6.17
|
0.31
|
-1.99
|
-0.51
|
-0.87
|
|
Peer Median
|
--
|
12.51
|
14.18
|
3.72
|
--
|
Net Margin
2.57
Lower than Peers by 0.53
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
2.57
|
1.57
|
1.36
|
1.38
|
0.77
|
|
Peer Median
|
3.10
|
3.56
|
4.62
|
4.10
|
--
|
Cash Profit Margin
4.76
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
4.76
|
3.50
|
3.69
|
3.72
|
3.12
|
|
Peer Median
|
--
|
0.00
|
--
|
0.00
|
--
|
Revenue Growth
-3.60
--
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
-3.60
|
5.78
|
3.91
|
4.83
|
-22.88
|
|
Peer Median
|
--
|
38.08
|
18.84
|
24.28
|
--
|
EBIT Growth
-2,033.92
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
-2,033.92
|
116.35
|
-306.73
|
38.67
|
-106.21
|
|
Peer Median
|
--
|
460.14
|
225.64
|
-15.80
|
--
|
Net Profit Growth
69.52
--
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
69.52
|
18.60
|
3.74
|
86.16
|
-89.22
|
|
Peer Median
|
--
|
-3.95
|
200.69
|
13.25
|
--
|
EPS Growth
69.50
--
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
69.50
|
-0.41
|
3.75
|
86.23
|
-89.22
|
|
Peer Median
|
--
|
90.91
|
--
|
13.25
|
--
|
Book Value Growth
1.23
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
1.23
|
18.00
|
0.73
|
0.71
|
0.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.22
Higher than Peers by 0.18
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
0.22
|
0.21
|
0.34
|
0.36
|
0.32
|
|
Peer Median
|
0.04
|
0.00
|
0.03
|
0.07
|
--
|
Short term debt to equity ratio
0.14
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
0.14
|
0.11
|
0.19
|
0.17
|
0.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.28
Higher than Peers by 2.19
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
4.28
|
4.81
|
2.72
|
2.91
|
2.86
|
|
Peer Median
|
2.10
|
2.00
|
2.04
|
2.16
|
--
|
Quick Ratio
3.55
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
3.55
|
3.77
|
2.09
|
2.23
|
2.15
|
|
Peer Median
|
--
|
3.80
|
3.16
|
2.23
|
--
|
Interest Coverage
1.53
Lower than Peers by 14.70
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
1.53
|
1.34
|
1.27
|
1.26
|
1.19
|
|
Peer Median
|
16.23
|
8.29
|
13.76
|
3.36
|
--
|
Operating Efficiency
Debtors to sales
34.53
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
34.53
|
33.75
|
34.38
|
35.83
|
34.52
|
|
Peer Median
|
--
|
27.50
|
40.47
|
26.09
|
--
|
Asset Turnover
0.30
--
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
0.30
|
0.33
|
0.32
|
0.32
|
0.31
|
|
Peer Median
|
--
|
1.26
|
1.17
|
0.64
|
--
|
Receivable days
126.89
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
126.89
|
120.91
|
125.67
|
125.49
|
145.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
167.70
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
167.70
|
161.71
|
164.60
|
167.38
|
166.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
57.59
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
57.59
|
99.15
|
155.50
|
136.81
|
149.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
237.00
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
237.00
|
183.46
|
134.78
|
156.07
|
162.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
62.24
Higher than Peers by 31.40
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
62.24
|
--
|
--
|
109.87
|
--
|
|
Peer Median
|
30.84
|
47.94
|
40.22
|
94.75
|
--
|
Price / Book Value
0.76
Lower than Peers by 5.62
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
0.76
|
--
|
--
|
0.77
|
--
|
|
Peer Median
|
6.38
|
4.56
|
4.89
|
3.81
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
0.08
|
--
|
--
|
--
|
EV/EBITDA
18.89
Lower than Peers by 11.15
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
18.89
|
20.74
|
19.34
|
20.18
|
20.09
|
|
Peer Median
|
30.04
|
35.83
|
23.03
|
-2.86
|
--
|
Market Cap
5
Lower than Peers by 264
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Ganga Pharma
|
5
|
--
|
--
|
4
|
--
|
|
Peer Median
|
268
|
133
|
112
|
40
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
